Table 1.

Baseline clinical and biochemical characteristics of individual patients

PatientAgeSexT RBTime Tac/CsATac/CsA DoseTac/CsA Trough LevelSBPDBPSCrGFRAlbProtIgG
126M814445.6124651.26984.12.901330
232M495147.0123541.341004.02.601234
354F382238.1132571.40973.81.90987
431M472847.112568.981014.02.201545
542M533646.911879.87974.13.201100
654M352947.1119651.44954.22.60657
762F645138.212467.891314.03.101342
871M835445.7125721.45804.43.18986
955M79473.5a198a125781.25843.972.291134
1045M908047.7114691803.80.71348
1149M968349115750.98944.22.7NA
1238M75213.6a150a106650.851153.81.85NA
1342M39243.7a175a115571.031134.11.77NA
  • TRB, time from renal biopsy in months; Time Tac/CsA, time on tacrolimus or cyclosporine A treatment in months; Tac/CsA dose, dose of tacrolimus (mg/day) or CsA (mg/Kg/day) at study entry; Tac/CsA trough levels, 12-trough levels (ng/ml); SBP, systolic blood pressure (mmHg), DBP, diastolic blood pressure (mmHg); SCr, serum creatinine (mg/dl); GFR, glomerular filtration rate (ml/min/1.73 m2; Alb, serum albumin (g/L); Prot, proteinuria (g/day); IgG, serum levels of immunoglobulin G (mg/dl)

  • a Patients treated with CsA and CsA trough levels.